A High-Throughput Fluorescence-Based Assay System for Appetite-Regulating Gene and Drug Screening

Yasuhito Shimada1,2,3,4, Minoru Hirano1, Yuhei Nishimura1,2,3,4, Toshio Tanaka1,2,3,4*

1 Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine, Tsu, Mie, Japan, 2 Mie University Medical Zebrafish Research Center, Tsu, Mie, Japan, 3 Department of Bioinformatics, Mie University Life Science Research Center, Tsu, Mie, Japan, 4 Department of Omics Medicine, Mie University Industrial Technology Innovation Institute, Tsu, Mie, Japan

Abstract

The increasing number of people suffering from metabolic syndrome and obesity is becoming a serious problem not only in developed countries, but also in developing countries. However, there are few agents currently approved for the treatment of obesity. Those that are available are mainly appetite suppressants and gastrointestinal fat blockers. We have developed a simple and rapid method for the measurement of the feeding volume of Danio rerio (zebrafish). This assay can be used to screen appetite suppressants and enhancers. In this study, zebrafish were fed viable paramecia that were fluorescently-labeled, and feeding volume was measured using a 96-well microplate reader. Gene expression analysis of brain-derived neurotrophic factor (bdnf), knockdown of appetite-regulating genes (neuropeptide Y, preproinsulin, melancortin 4 receptor, agouti related protein, and cannabinoid receptor 1), and the administration of clinical appetite suppressants (fluoxetine, sibutramine, mazindol, phentermine, and rimonabant) revealed the similarity among mechanisms regulating appetite in zebrafish and mammals. In combination with behavioral analysis, we were able to evaluate adverse effects on locomotor activities from gene knockdown and chemical treatments. In conclusion, we have developed an assay that uses zebrafish, which can be applied to high-throughput screening and target gene discovery for appetite suppressants and enhancers.

Introduction

Most vertebrates can store a considerable amount of energy as fat for later use. This ability is currently responsible for major health risks facing humans worldwide. These risks include obesity and metabolic syndrome associated with cardiovascular disease. The predisposition to develop obesity can theoretically result from any pathological malfunction or lack of adaptation to changing environments [1]. The mechanism of feeding adaptation to obtain the correct amount of food is a response to the energy requirement of the body, amount of body fat, and blood glucose concentration. This is mediated by signaling molecules such as leptin and insulin [2]. Information is then transmitted to the central nervous system to regulate appetite [3–5]. In the short-term, such as during feeding, food consumption is regulated by several gut hormones, including cholecystokinin [6], peptides YY [7], oxyntomodulin [8], and neuropeptide Y (NPY) [9,10]. These multi-organ mechanisms of appetite regulation make it difficult to discover appetiteregulating targets and agents, resulting in very few FDA approved drugs for treating obesity and metabolic syndrome. In drug discovery, high-throughput screening (HTS) is the most efficient method to detect appetite suppressants and promoters, because conventional rodent-feeding quantification systems require intensive labor, time, and many animals [11]. This makes it almost impossible to find lead compounds from libraries of chemicals with varying concentrations with several genetic interventions. Thus, there is an urgent need for new feeding behavior assays using alternative animal models with HTS capacity. Over the last decade, to overcome the bottlenecks surrounding throughput and complexity in whole-animal testing, phenotype-based screening of Danio rerio (zebrafish) has emerged as a powerful tool for identifying small bioactive compounds. The use of zebrafish has many advantages over traditional models, as they are simple to maintain, have a high reproductive capacity, and develop rapidly. Additionally, fluorescence-based zebrafish screening using reporter-based transgenes allows visualization through their transparent body walls, allowing for HTS. Compared with other model organisms used in drug screening (yeast, nematodes, and fruit flies), zebrafish possess many evolutionary and morphological similarities to humans [12]. Also, various models of human disease have been established in zebrafish [13–15] for genetic disorders [16] and diet-induced obesity [17,18]. For appetite regulation, zebrafish npy [10], agouti-related protein [16], melatonin 4 receptor, and melanin 19] are well conserved in appetite or metabolic regulation. These features make this species a versatile tool for pre-clinical drug discovery and toxicological investigation.

The aim of our study was to create a simple in vivo HTS system to evaluate feeding volume. Here, we present a novel feeding evaluation assay using zebrafish larvae with fluorescently-labeled live bait, paramecia. Living paramecia is one of the most suitable
foods for zebrafish and other small fish larvae because of its nutritional components and appetite induction in young fish [20,21]. In addition, using knockdown experiments and known human appetite suppressants, we demonstrated that the genes and drug responses involved in appetite regulation are very similar in zebrafish and mammals.

Materials and Methods

Ethics Statement

All animal experiments were conducted according to the ‘Act on Welfare and Management of Animals’ (Ministry of Environment of Japan) and complied with international guidelines. Ethics approval from the local Institutional Animal Care and Use Committee was not sought, since this law does not mandate protection of fish. After the experiments, the fish were sacrificed by anesthetic overdose.

Chemicals

Fluoxetine hydrochloride and phentermine hydrochloride were purchased from Sigma-Aldrich (St Louis, MO, USA). Sibutramine hydrochloride monohydrate was purchased from Wako Pure Chemicals (Tokyo, Japan). Mazindol was purchased from Tokyo Kasei (Tokyo, Japan). Rimonabant hydrochloride was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Stock solutions (10 mM) of the drugs were prepared in dimethyl sulfoxide (Sigma-Aldrich). The anesthetic used was 3-aminobenzoic acid ethyl ester (tricaine, MS-222), which was also purchased from Sigma-Aldrich. For anesthesia, 1.6 mg/ml tricaine was dissolved in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, and 0.33 mM MgSO4) supplemented with 5 mM HEPES and adjusted to pH 7.0. This was a 10× anesthetic solution for use in young zebrafish.

Zebrafish Breeding

Zebrafish (AB strain) were obtained from the Zebrafish International Resource Center of the University of Oregon. Fish were maintained on a 14:10 h light:dark cycle and bred in our laboratory according to standard conditions [21]. Embryos obtained from natural mating were kept in E3 medium at 28°C.

Preparation of Fluorescently-labeled Paramecia

Paramecia were a kind gift from Dr. K. Araki (National Research Institute of Aquaculture, Mie, Japan). Paramecia were cultured in medium consisting of one tablet of dry yeast (EBIOS, Asahi Food and Healthcare, Tokyo, Japan), and four grains of wheat germ dissolved in 1 l of distilled water. At the appropriate density, paramecia culture medium was transferred into a shading bottle, whose upper part was transparent. Since paramecia are attracted to light, they were collected from the culture medium close to the surface. The collected paramecia medium was filtered through a coarse mesh (112 µm) filter (PP-112n; Kyoshin Riko, Tokyo, Japan) to remove debris, and then filtered through a fine mesh (20 µm) filter (PP-20n; Kyoshin Riko) to obtain pure paramecia. The paramecia were then resuspended in 50 ml of distilled water. To concentrate the purified paramecia, the suspension was centrifuged at 3,000 rpm with a Kubota 8800 centrifuge (Kubota, Tokyo, Japan) for 5 min and resuspended again in 1 ml of distilled water. Paramecia were quantified by measuring the optical density (500 nm) of a 10-fold dilution using a spectrophotometer (Beckman DU600 spectrophotometer, Beckman Instruments, Fullerton, CA, USA). The following calculation was used to determine the amount of paramecia: paramecia (P) = optical density of the 10-fold dilution at 500 nm (OD500) × 10 x volume (V) in µl. For fluorescent labeling of paramecia, we used the lipophilic tracer 4-(4-(didecylamino)styryl)-N-methylpyridinium iodide (4-De-10-ASP; Invitrogen, Carlsbad, CA, USA), which is usually used for live-cell staining in neurons [22], hair cells [23], and cancer cells for xenotransplantation [24]. Almost 1000 P of paramecia were suspended in 1 ml of distilled water, then 25 µg/ml 4-De-10-ASP was added. The suspension was gently mixed by inverting the tube. After 1 h of staining, paramecia were washed, by centrifuging, to remove residual 4-De-10-ASP.

Quantification of Paramecia Intake

In zebrafish, the rostral digestive tract is fully functional by 3 days post-fertilization (dpf), when the lumen of the posterior pharynx is visible and the mouth is open, and posteriorly, when the anus is open at 4 dpf [23]. Thus, we conducted labeled paramecia feeding from 5 dpf until 10 dpf because of optimal body wall transparency and size for the 96-well plates. We conducted paramecia feeding in 6-well plates to allow for free swimming of zebrafish. At 12 h before feeding with paramecia, 15 larvae per condition were transferred into 6-well plates containing 3 ml of E3 medium. A total of 1000 P of fluorescent paramecia were added into each well. Two hours after feeding, larvae were anesthetized. After two washes with fresh E3 medium to remove residual paramecia, each larva was transferred into a 96-well round bottom black plate (3792; Corning, Lowell, MA, USA) together with 20 µl of anesthetic solution. The intra-abdominal fluorescent signal was measured using the Victor2 fluorescent plate reader (PerkinElmer, Boston, MA, USA); in well scan mode (10×10 multipoint/well, 0.1 s/point, 5 repeats) using a fluorescein filter set (excitation wavelength 485 nm, emission wavelength 535 nm). The sum of each point was defined as proportional to the amount of paramecia fed to each zebrafish.

Swimming Behavioral Analyses

To determine whether gene knockdown and drug treatment negatively affected zebrafish neurobehavioral function, swimming behavior was analyzed as previously described [26], with some modifications. One hour prior to evaluation, a fish was removed from each experimental unit and placed in a well with 50 µl of E3 medium in a 96-well clear bottom plate for acclimatization. The fish were then video recorded for 15 min, and the resulting footage evaluated for swimming distance using the EthoVision XT system (version 8.0; Noldus Information Technology, Wageningen, The Netherlands).

Drug Treatment

The following drugs were used in treatments: fluoxetine, a selective serotonin reuptake inhibitor; sibutramine, a serotonin and noradrenaline reuptake inhibitor; mazindol, a catecholine reuptake inhibitor; phentermine, a catecholine releaser; and rimonabant, a cannabinoid type 1 receptor antagonist. Drugs were added to fish in 6-well plates for 12 h before feeding with paramecia.

Gene Knockdown and mRNA Rescue

For targeted gene knockdown, morpholino antisense oligonucleotides (MO) were synthesized by GeneTools (Philomath, OR, USA). The MO sequences are shown in Table 1. Each MO was modified with a lipophilic tracer 4-(4-(didecylamino)styryl)-N-methylpyridinium iodide (4-De-10-ASP; Invitrogen, Carlsbad, CA, USA), which is usually used for live-cell staining in neurons [22], hair cells [23], and cancer cells for xenotransplantation [24]. Almost 1000 P of paramecia were suspended in 1 ml of distilled water, then 25 µg/ml 4-De-10-ASP was added. The suspension was gently mixed by inverting the tube. After 1 h of staining, paramecia were washed, by centrifuging, to remove residual 4-De-10-ASP.
GeneTools) was injected into embryos. The MO solution was mixed with 50 ng/μl of pXII-GFP plasmid [27], and used as a marker for MO introduction. For mRNA synthesis, we amplified the open reading frames of \textit{insa} and \textit{npy} by PCR and inserted \textit{EcoRI/Smal} and \textit{XhoI/Sall} sites, respectively, into the pTNT vector (Promega, Madison, WI, USA) using a Mighty Mix DNA Ligation Kit (Takara Bio, Ohtsu, Japan). All restriction enzymes were purchased from New England Biolabs (Beverly, MA, USA). To rescue \textit{insa} and \textit{npy} MO-induced appetite suppression, 200 pg of synthesized mRNA per embryo were co-injected with each MO.

Total RNA Extraction

Larvae were exposed to fluoxetine and sibutramine in 6-well plates at 5 dpf and sacrificed 12 h after deep anesthetization. For total RNA extraction from the brain, the epidermis, gills, swim bladder and intestinal tract of each larva were removed. Larvae were dissected so that individual brain regions could be obtained [28]. Dissected tissues were immersed in RNAlater (Life Technologies, Grand Island, NY, USA). To rescue \textit{insa} and \textit{npy} MO were then synthesized using mMessage Machine (Ambion Life Technologies, Grand Island, NY, USA). To rescue \textit{insa} and \textit{npy} mRNA synthesis, we amplified the open reading frames of \textit{mc4r} using a Mighty Mix DNA Ligation Kit (Takara Bio, Ohtsu, Japan). All restriction enzymes were purchased from New England Biolabs (Beverly, MA, USA). To rescue \textit{insa} and \textit{npy} MO introduction. For mRNA synthesis, we amplified the open reading frames of \textit{insa} and \textit{npy} by PCR and inserted \textit{EcoRI/Smal} and \textit{XhoI/Sall} sites, respectively, into the pTNT vector (Promega, Madison, WI, USA) using a Mighty Mix DNA Ligation Kit (Takara Bio, Ohtsu, Japan). All restriction enzymes were purchased from New England Biolabs (Beverly, MA, USA). To rescue \textit{insa} and \textit{npy} MO-induced appetite suppression, 200 pg of synthesized mRNA per embryo were co-injected with each MO.

Table 1. Morpholino oligonucleotides used in the present study.

| Target gene                  | Locus ID    | MO name | Sequence (5’ - 3’)            | Type of inhibition |
|------------------------------|-------------|---------|--------------------------------|--------------------|
| preproinsulin a              | NM_131056   | insa MO | GCA CCA GCC TGA ACG CAC ACT GCC A | Translational      |
| preproinsulin b              | NM_001039064| insb MO | GTG GAC ACA GAC TGA GGA CAT CCA C | Translational      |
| neuropeptide y               | NM_131074   | npy MO  | CCA CAT CTT CAT GGT ATT CAT C  | Translational      |
| brain-derived neurotrophic factor | NM_131595 | bdnf MO | GCT GAA TGG TCT CCT TTA CGA CTG G | Translational      |
| melanocortin 4 receptor      | NM_173278   | mc4r MO1| ATGATGATGTGAGGTGTTCATTTCC    | Translational      |
| agouti related protein homolog | XM_001923904| agrp MO1| GGGAGTGGCTATGATGTCACAAAA    | Splicing           |
| cannabinoid receptor 1       | NM_212820   | cnr1 MO | GTGCTATCAACACATACCTTTTG     | Splicing           |
Table 2. Primer sequences used in the present study.

| Gene symbol | Gene name             | Locus ID  | Purpose       | Forward primer sequence (5’-3’)                  | Reverse primer sequence (5’-3’)               |
|-------------|-----------------------|-----------|---------------|-------------------------------------------------|-----------------------------------------------|
| insa        | preproinsulin a       | NM_131056 | Cloning       | TCGAATTTCATGGCACTGTTGCTTGCAGG                  | AGCCTCTGATGACATGTCAGCTGAGCCCTA               |
| npy         | neuropeptide y        | NM_131074 | Cloning       | GTCTCCAGAGTAATCCAAACACATGAGAT                 | TCTAGTTAAACCCCTACACTGTCGACTA                |
| actb1       | actin, beta 1         | NM_131031 | QPCR          | GACTTCCACAGAGGTATCC                           | GGTGATGTAATGTCCTAGTCTGGTG                 |
| bdnf        | brain-derived neurotrophic factor | NM_131595 | QPCR          | ATAGTAACGAACAGGATTG                          | GTCAGTCATGGAGATCC                           |
| slc6a4a     | solute carrier family 6, member 4A | NM_001039972 | QPCR          | CATCTATGCGAGCGCATATGG                        | AAGAATATGATGGCGAA                           |
| htr1aa      | serotonin receptor type 1a | NM_001123321 | QPCR          | ATAGGATGACGGGAGGATG                           | CAATCAGCGGAGAACCAG                        |
| htr1ab      | serotonin receptor type 1b | NM_001145766 | QPCR          | CTGTTGCGCTGCACCTTTC                         | TGAATCTCAAAGACTGCGG                           |
| agrp        | agouti related protein | XM_001923904 | PCR for MO inhibition | GGCTGGTTTTGGTGAATGT                 | TCGTTTTGTAGGGTGTGTC                        |
| cnr1        | cannabinoid receptor 1 | NM_212820 | PCR for MO inhibition | ACGTACAGAAGAGCGCTG                          | GGCATTTTCACAGGGCTGTC                         |
| pTNT        | Expression vector pTNT | AF479322  | Cloning       | AAGGCTAGATCATTAAATACCA                      | GTCAATTCCGCCATACCA                          |

Underline indicates the restriction enzyme recognition sites.

doi:10.1371/journal.pone.0052549.t002

followed by Dunnett’s test for multiple comparisons was used. A P-value less than 0.05 was considered statistically significant.

Results

Zebrafish Feeding Assay using Fluorescently-labeled Paramecia

A schematic representation of the zebrafish feeding assay is summarized in Figure 1A. The numbers of paramecia in distilled water correlated to the absorbance at 500 nm (Fig. 1B), therefore we were able to estimate how many paramecia were present in each experiment. The lipophilic tracer 4-Di-10-ASP, stained paramecia for at least 3 days without any leakage from their bodies, and had no effect on morbidity and motility. After 4-Di-10-ASP labeling, paramecia levels were directly proportional to fluorescent intensity (Fig. 1C). Fluorescent signals from ingested paramecia in the abdominal area were measured. It was difficult to determine the exact location of the gut for each larva, therefore fluorescent intensity was measured at multiple points. The relationship between the amount of introduced and ingested paramecia can be clearly seen (Fig. 1D). Two hours after feeding, fluorescent intensities increased, depending on the amount of paramecia. In addition, free feeding of the maximum volume of paramecia (1000 P) showed that the feeding volume peaked 1 h after feeding started (Fig. 1E). At 0.5 and 3 h after feeding had started, the fluorescent intensity was significantly less than that at 1 h (P<0.05). At 4 h, fluorescent intensity was further reduced (P<0.01). There was no significant difference in fluorescent intensity between 1 and 2 h after feeding. Thus, these data suggested that the peak of feeding volume existed during 1–3 h after feeding. Following these experiments, the feeding time was set at 2 h, which ensured enough time for maximum paramecia intake.

Gene Expression Related to Regulation of Appetite in Zebrafish and Humans

To test whether the zebrafish feeding assay could be used to explore appetite-regulation in mammalian species, we conducted gene expression analysis and knockdown studies. Brain-derived neurotrophic factor (BDNF) is one of the most important anorexigenic factors in the mammalian hypothalamus and regulates feeding behavior to stop feeding [29]. In zebrafish, bdnf mRNA expression was significantly increased (P<0.05) within 30 min of the initiation of feeding (Fig. 2A). Feeding-induced bdnf expression stimulates the satiety center and is a common mechanism of appetite regulation in vertebrates. We next conducted gene knockdown experiments using MO with appetite-regulating genes and mRNA rescue experiments. The knockdown efficacies of npy MO and insa MO were confirmed by western blotting (Fig. 2B and C). The knockdown of npy, a major orexigenic hormone also found in zebrafish [10], decreased food intake by 67% compared with the control-MO injected group at 7 dpf (P<0.05; Fig. 2D). Conversely, knockdown of insa, an ortholog of the human precursor of insulin, preproinsulin [30], increased food intake by 41% (Fig. 2E; P<0.05). The effects on appetite modulation induced by npy and insa MO were rescued by each mRNA co-injection (Fig. 2F and G). Knockdown of npy and insa had no effect on the distance of spontaneous swimming (Fig. 2F and G). Zebrafish have another insulin paralog, preproinsulin b (insb), derived from gene duplication [30]. insb expression peaked at 1 dpf, and insb knockdown caused severe abnormalities, high mortality, and virtually eradicated the population by 5 dpf. In addition, bdnf knockdown caused severe pericardial swelling and reduced locomotor activity similar to a previous study [31]. We conducted melanocortin 4 receptor (mc4r), agouti-related protein (agrp), and cannabinoid receptor 1 (cnr1) knockdown (Table 3). The mc4r gene is a major orexigenic gene in zebrafish appetite regulation systems [33]. And the mc4r MO injection increased food intake (P<0.05). Regarding agrp, a strong inhibitor of melanocortin systems in fish and mammals, the agrp MO significantly decreased (P<0.05) food intake and locomotor activity. The cnr1 MO decreased locomotor activity (P<0.01) with suppression of feeding behavior. The knockdown efficacies of these splicing inhibitor MOs (agrp MO1, 2 and cnr1 MO) were confirmed by PCR (Fig. 2H).
Figure 1. Zebrafish feeding assay using 4-Di-10-ASP labeled paramecia. (A) Schematic representation of the feeding assay. (B) The actual numbers of paramecia correlated with optical density at 500 nm (OD500). (C) Correlation between the relative amount of paramecia (P) and fluorescent intensity. (D) Fluorescent intensities of ingested paramecia in zebrafish. The fluorescent intensities of paramecia in zebrafish abdomen increased independently to the numbers of introduced-paramecia. All values are mean ± SEM, n = 15. (E) Fluorescent intensities after free-feeding of 4-10-Di-ASP-labeled paramecia. Fluorescent intensities of ingested paramecia were at maximum levels 1–3 h after feeding. All values are mean ± SEM, n = 15, *P<0.05, **P<0.01 compared with 1 h after feeding.

doi:10.1371/journal.pone.0052549.g001
Appetite Suppressant Treatment in Zebrafish

We validated whether appetite suppressants decrease zebrafish larvae feeding in the assays we developed. The feeding evaluation results after the administration of fluoxetine (Fig. 3A), sibutramine (Fig. 3B), mazindol (Fig. 3C), phentermine (Fig. 3D), and rimonabant (Fig. 3E) can be clearly seen. Overnight treatment with these drugs suppressed food intake in a dose-dependent manner despite different anorexic mechanisms for each of the drugs. In addition, the drugs had no effect on morbidity or motility during the experiments. Figure 4 shows the distance of spontaneous swimming. Of the drugs used in this study, only rimonabant at 0.3 and 1 μM significantly decreased (P<0.05) the distance moved compared with controls (Fig. 4E).

Gene Expression Analysis Following Fluoxetine and Sibutramine Treatment

We performed gene expression analyses on fluoxetine- and sibutramine-treated zebrafish. Fluoxetine treatment decreased npy expression in a dose-dependent manner, but increased serotonin transporter (slc6a4a) expression (P<0.01; Fig. 5A and 5B). Sibutramine treatment (10 μM) induced serotonin receptor type 1aa (ht1aa) and 1ab (ht1ab) expression (P<0.01; Fig. 5G and Fig. 5H).

Discussion

In vivo Appetite-HTS System using Zebrafish

Several zebrafish-based behavioral assays for scototaxis (anxiety-like behavior in fish) [33], thigmotaxis [34], and social interaction...
have been developed, and allow the evaluation of neurotransmitter systems for target genes and drug discovery [36]. For feeding behavior assays, prey capture tracking techniques using larvae [37,38], measuring the volume of food consumed [32], and monitoring Artemia numbers [18] using adult zebrafish have been reported. The aim of the current study was to create a simple in vivo HTS system to evaluate feeding volume. We selected zebrafish larvae because they can be used in a 96-well format. In combination with our fluorescence-based feeding assay and other conventional neurobehavioral analyses, we were able to evaluate potential pharmacological and toxicological targets of feeding behavior using HTS.

Conservation of Appetite-regulating Gene Function between in Humans and Zebrafish

Previous studies have shown conservation of gene function in several neurobehavioral responses against psychotropic drugs, and for neurobehavioral toxicities between human and zebrafish.

### Table 3. Effects of morpholinos on food intake and locomotor activity.

| Target gene | MO name | Food intake (ratio to Std MO) | Distance of spontaneous swimming (ratio to Std MO) |
|-------------|---------|------------------------------|-----------------------------------------------|
| npy         | npy MO  | 0.33±0.17*                   | 1.12±0.16                                     |
| insa        | insa MO | 1.41±0.29*                   | 0.88±0.12                                     |
| insb        | insb MO | (lethal)                     | (lethal)                                      |
| bdnf        | bdnf MO | nd                           | 0.01±0.00**                                   |
| mcr4        | mcr4 MO1| 1.38±0.32*                   | 0.93±0.15                                     |
|             | mcr4 MO2| 1.45±0.23*                   | 1.05±0.21                                     |
| agrp        | agrp MO1| 0.64±0.17*                   | 0.42±0.20*                                    |
|             | agrp MO2| 0.72±0.13*                   | 0.58±0.21*                                    |
| cnr1        | cnr1 MO | 0.27±0.16**                  | 0.19±0.11**                                   |

n = 16, *P<0.05, **P<0.01. All values are mean ± SEM. nd; not detected. Red color indicates increase and green color indicates decrease in each parameter.

doi:10.1371/journal.pone.0052549.t003

Figure 3. Effect of appetite suppressants on feeding volume. Effects of appetite-regulating drugs that are used clinically in humans affected zebrafish larvae. (A) Fluoxetine, (B) Sibutramine, (C) Mazindol, (D) Phentermine, and (E) Rimonabant treatment decreased feeding volume in young zebrafish (7 dpf). All values are mean ± SEM, n = 16, *P<0.05, **P<0.01.

doi:10.1371/journal.pone.0052549.g003
Figure 4. Effect of appetite suppressants on locomotor activities. The effects of appetite-regulating drug treatment on spontaneous swimming (15 min) were measured in young zebrafish. (A) Fluoxetine, (B) Sibutramine, (C) Mazindol, (D) Phentermine, and (E) Rimonabant. All values are mean ± SEM, n = 16, *P < 0.01.
doi:10.1371/journal.pone.0052549.g004

Figure 5. Gene expression analyses following fluoxetine and sibutramine treatment. Downstream genes of appetite regulation in young zebrafish brains were measured after treatment with fluoxetine (A–D) and sibutramine (E–H). (A and E) npy, (B and F) slc6a4, (C and G) htr1aa, and (D and H) htr1ab. All values are mean ± SEM, n = 4, *P < 0.05, **P < 0.01.
doi:10.1371/journal.pone.0052549.g005
signaling, were highly conserved in zebrafish. NPY, insulin, 5-HT, melanocortin and central adrenergic antagonism in neurobehavioral disorders, such as Parkinson’s and fasciculation during brain development [53], and suppresses appetite regulation, and could be a target for rimonabant [51,52]. It is possible that suppression of somatic development following agrp knockdown at 6 dpf larvae, as previously reported [47]. It is possible that suppression of somatic development induced by the agrp MO can inhibit feeding behavior independent of the activation of melanocortin signaling.

The endocannabinoid receptor cnr1, mediates the psychoactive effect of marijuana and addiction [49]. It is also expressed in the periventricular hypothalamus of zebrafish [50]. This possibly suggests that cnr1 in zebrafish may share the same function in appetite regulation, and could be a target for rimonabant [51,52]. Knockdown of cnr1 decreased the spontaneous locomotion (Table 3). The cnr1 MO probably inhibits normal axonal growth and fasciculation during brain development [53], and suppresses locomotor activity. This corresponds with the results of CNR1 antagonism in neurobehavioral disorders, such as Parkinson’s disease [54] and our result of rimonabant treatment (Fig. 3E and 4E).

Anorexic Drug Response in Zebrafish

Zebrafish exhibited significant suppression of their appetites in response to anorexic drugs. Fluoxetine (Fig. 3A) is a selective serotonin reuptake inhibitor (SSRI) used for the treatment of clinical depression, anxiety disorder, obsessive-compulsive disorder, and bulimia. SSRIs are potent and highly selective inhibitors of the transporter enzyme for serotonin (5-HT) reuptake at the presynaptic membrane, causing an increase in 5-HT concentrations at postsynaptic receptor sites [55]. Serotonin transporter genes are also conserved in zebrafish [56,57]. It is well known that 5-HT plays an inhibitory role in the control of ingestive behavior, and that the administration of fluoxetine suppresses food intake and weight gain under free-feeding and food-restricted conditions [58]. In addition, it has been shown that fluoxetine reduces mRNA expression levels of Npy in rat brain [59]. Feeding behavior is also regulated by npy in zebrafish (Fig. 2D). The expression of npy in brain regions following fluoxetine treatment decreased in a dose-dependent manner (Fig. 5A), demonstrating that mechanisms regulating appetite are highly preserved between zebrafish and mammals. Serotonin transporter (slc6a4) mRNA was induced by fluoxetine treatment (Fig. 5B). In a previous study, sub-chronic administration of fluoxetine in rodents increased Slc6a4 expression in the midbrain raphe [60], indicating a similarity in serotoninergic appetite regulatory mechanisms in vertebrates. However, the time-course for fluoxetine pharmacodynamics in zebrafish is shorter than that in mammals. The expression of serotonin receptor type laa (htr1aa) and lab (htr1ab) were not altered by fluoxetine treatment, consistent with previous studies [61]. Sibutramine, a central-acting serotonin-norepinephrine reuptake inhibitor [62], also reduces food intake in zebrafish (Fig. 3B). In contrast to fluoxetine treatment, sibutramine did not result in a decrease in npy expression in brain regions (Fig. 5E). This result was also consistent with a previous study [63]. A high dose of sibutramine (10 μM) induced htr1aa and htr1ab expression, suggesting hypersensitivity and activation of 5-HT signaling, possibly increasing the anorexic effects of sibutramine. The adrenergic system of zebrafish has been well characterized by many researchers, and 2α-adrenoceptors have been shown to be expressed in the hypothalamus [64]. These findings suggest the involvement of adrenergic signaling in the satiety center of the zebrafish brain, similar to that seen in mammals [65]. Mazindol, a reuptake inhibitor of norepinephrine and phentermine (a releaser of norepinephrine), acts on the hypothalamus to stimulate the adrenal glands to increase norepinephrine, subsequently reducing hunger in zebrafish (Fig. 3C and D).

Appetite-HTS with Evaluation of Locomotor Activities

Appetite suppressants exhibit many severe central nervous system side effects including depression, agitation, and anxiety [66], which have sometimes been reflected in locomotor activities in animal models. Thus, there is a need for the evaluation of appetite with, at the very least, locomotor activities under similar conditions to that of animal experiments. In the current study, rimonabant significantly suppressed appetite volume (Fig. 3E) and locomotor activities (Fig. 4E), which was consistent with cnr1 knockdown (Table 3). In addition to appetite suppression, rimonabant is associated with several adverse psychiatric events including depression and anxiety in humans [67,68]. Rimonabant-induced suppression of locomotor activities in zebrafish likely reflects the clinical situation. In addition, it has been reported that serotonergic stimulation decreases locomotor activity in zebrafish [28], however we did not observe this in the current study. The reason for this difference is likely because of the shorter exposure time in this study compared with that in the previous study (10 μM for 12 h vs. 10 μM for 24 h). An intravenous injection of fluoxetine was not associated with significant effects on locomotor activity in chinook salmon [69]. In contrast to rimonabant, catecholaminergic stimulation (10 μM mazindol or 30 μM phentermine) increased spontaneous swimming without any effects on survival rate (data not shown), which corresponds to previous results seen in rodents [70,71].

Conclusion

Clinical appetite suppressants are associated with adverse effects due to inappropriate non-selective activity on signaling pathways, suggesting that drug targets of appetite regulation require further research. Both hyperphagia and anorexia are disorders related to dysregulation of appetite and urgently require treatment regimens without any adverse side effects. To address this problem, our fluorescence-based zebrafish feeding assay is a powerful tool in combination with MO knockdown or mutation screening. In summary, we have demonstrated a new high-throughput assay system for appetite-regulating drug screening and target gene discovery with high relevance to human diseases.
Acknowledgments

We thank A. Suzuki and S. Ichikawa for their experimental assistance and K. Nishiguchi and R. Ikeyama for their secretarial assistance.

References

1. Berthoud HR, Morrison C (2008) The brain, appetite, and obesity. Annu Rev Psychol 59: 55–92.
2. Aromon IJ, Thornton-Jones ZD (2007) New targets for obesity pharmacotherapy. Clin Pharmacol Ther 81: 748–752.
3. Geroussidis K (2004) Brain insulin and feeding: a bi-directional communication. Eur J Pharmacol 490: 59–70.
4. Rowland NE, Maiten A, Li BH (1996) The physiology and brain mechanisms of feeding. Nutrition 12: 626–639.
5. Schwartz MW, Seelye RJ (1997) The new biology of body weight regulation. J Am Diet Assoc 97: 54–58.
6. Schanzer MC, Jacobson ED, Dafny N (1978) Endocrine control of appetite: gastrointestinal hormonal effects on CNS appetitive structures. Neuroendoce- tory 25: 329–342.
7. Inui A, Oka M, Nakajima M, Inoue T, Sakatani N, et al. (1991) Neuropeptide regulation of feeding in dogs. Am J Physiol 261: R338–394.
8. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, et al. (2001) Oxytocin modulates expression of antisaccadic motor activity by Campani torus in a zebrafish diet-induced obesity model. Nutr Metab (Lond) 8: 88.
9. Varga ZM (2011) Aquaculture and husbandry at the zebrafish international research center. Methods Cell Biol 104: 453–478.
10. Westerfield M (2007) The Zebrafish Book: A guide for the laboratory use of the zebrafish Danio rerio. 2 ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
11. Yokobori E, Azuma M, Nishiguchi R, Kang KS, Kamijo M, et al. (2012) Neuropeptide Y stimulates food intake in the zebrafish, Danio rerio. J Neuroendocrinol 24: 766–773.
12. Kanarek RB, Marks-Kaufman R (1988) Animal models of appetitive behavior: interaction of nutritional factors and drug seeking behavior. Curr Concepts Nutr 16: 1–25.
13. Schlegel A, Stainer DY (2007) Lessons from “lower” organisms: what worms, flies, and zebrafish can teach us about human energy metabolism. PLoS Genet 3: e199.
14. Inui A, Oka M, Nakajima M, Inoue T, Sakatani N, et al. (1991) Neuropeptide regulation of feeding in dogs. Am J Physiol 261: R338–394.
15. Tanaka T, Oka T, Shimada Y, Umemoto N, Kuroyanagi J, et al. (2008) Pharmacogenomics of cardiovascular pharmacology: pharmacogenomic net- work of cardiovascular disease models. J Pharmacol Sci 107: 8–14.
16. Kinkel MD, Prince VE (2009) On the diabetic menu: zebrafish as a model for work of cardiovascular disease models. J Pharmacol Sci 107: 8–14.
17. Oka T, Nishimura Y, Zang L, Hirano M, Shimada Y, et al. (2010) Diet-induced obesity in zebrafish shares common pathophysiological pathways with mammalian obesity. BMC Physiol 10: 21.
18. Nakamura A, Unuyama T, Kato H, Nishino T, Oshita Y, et al. (2009) The first selective serotonin uptake inhibitor and an antidepressant drug: twenty years of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants. J Neurochem 21: 161–190.
19. Debons AF, Krimsky I, From A (1970) A direct action of insulin on the hypothalamic satiety center. Am J Physiol 219: 938–943.
20. Figlewicz DP, Bennett JL, Alkhatib S, Zavosh A, Sipol AJ (2008) Insulin acts at different CNS sites to decrease acute sucrose intake and sucrose self-administration in rats. Am J Physiol Regul Integr Comp Physiol 295: R383–394.
21. Oka T, Nishimura Y, Zang L, Hirano M, Shimada Y, et al. (2010) Diet-induced obesity in zebrafish shares common pathophysiological pathways with mammalian obesity. BMC Physiol 10: 21.
22. Nakamura A, Unuyama T, Kato H, Nishino T, Oshita Y, et al. (2009) The first selective serotonin uptake inhibitor and an antidepressant drug: twenty years of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants. J Neurochem 21: 161–190.
23. Debons AF, Krimsky I, From A (1970) A direct action of insulin on the hypothalamic satiety center. Am J Physiol 219: 938–943.
24. Figlewicz DP, Bennett JL, Alkhatib S, Zavosh A, Sipol AJ (2008) Insulin acts at different CNS sites to decrease acute sucrose intake and sucrose self-administration in rats. Am J Physiol Regul Integr Comp Physiol 295: R383–394.
25. Oka T, Nishimura Y, Zang L, Hirano M, Shimada Y, et al. (2010) Diet-induced obesity in zebrafish shares common pathophysiological pathways with mammalian obesity. BMC Physiol 10: 21.
26. Nakamura A, Unuyama T, Kato H, Nishino T, Oshita Y, et al. (2009) The first selective serotonin uptake inhibitor and an antidepressant drug: twenty years of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants. J Neurochem 21: 161–190.

Author Contributions

Conceived and designed the experiments: YS TT. Performed the experiments: YS MH. Analyzed the data: YS MH YN. Contributed reagents/materials/analysis tools: MH. Wrote the paper: YS YN TT.

Fluorescence-Based Zebrafish Feeding Assay

Acknowledgments

We thank A. Suzuki and S. Ichikawa for their experimental assistance and K. Nishiguchi and R. Ikeyama for their secretarial assistance.

References

1. Berthoud HR, Morrison C (2008) The brain, appetite, and obesity. Annu Rev Psychol 59: 55–92.
2. Aromon IJ, Thornton-Jones ZD (2007) New targets for obesity pharmacother- apy. Clin Pharmacol Ther 81: 748–752.
3. Geroussidis K (2004) Brain insulin and feeding: a bi-directional communication. Eur J Pharmacol 490: 59–70.
4. Rowland NE, Maiten A, Li BH (1996) The physiology and brain mechanisms of feeding. Nutrition 12: 626–639.
5. Schwartz MW, Seelye RJ (1997) The new biology of body weight regulation. J Am Diet Assoc 97: 54–58.
6. Schanzer MC, Jacobson ED, Dafny N (1978) Endocrine control of appetite: gastrointestinal hormonal effects on CNS appetitive structures. Neuroendoce- tory 25: 329–342.
7. Inui A, Oka M, Nakajima M, Inoue T, Sakatani N, et al. (1991) Neuropeptide regulation of feeding in dogs. Am J Physiol 261: R338–394.
8. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, et al. (2001) Oxytocin modulates expression of antisaccadic motor activity by Campani torus in a zebrafish diet-induced obesity model. Nutr Metab (Lond) 8: 88.
9. Varga ZM (2011) Aquaculture and husbandry at the zebrafish international research center. Methods Cell Biol 104: 453–478.
10. Westerfield M (2007) The Zebrafish Book: A guide for the laboratory use of the zebrafish Danio rerio. Fifth edition: University of Oregon Press.
11. Ahmed FA, Chaudhary P, Sharma SC (2001) Effects of increased intracar- diac pressure on rat retinal ganglion cells. Int J Dev Neurosci 19: 209–218.
12. Hernandez PP, Moreno V, Olivar FA, Allende ML (2006) Sub-lethal concentrations of waterborne copper are toxic to lateral line neurones in zebrafish (Danio rerio). Hear Res 213: 1–10.
13. Nakamura A, Unuyama T, Kato H, Nishino T, Oshita Y, et al. (2009) The first selective serotonin uptake inhibitor and an antidepressant drug: twenty years of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants. J Neurochem 21: 161–190.
14. Debons AF, Krimsky I, From A (1970) A direct action of insulin on the hypothalamic satiety center. Am J Physiol 219: 938–943.
15. Figlewicz DP, Bennett JL, Alkhatib S, Zavosh A, Sipol AJ (2008) Insulin acts at different CNS sites to decrease acute sucrose intake and sucrose self-administration in rats. Am J Physiol Regul Integr Comp Physiol 295: R383–394.
16. Oka T, Nishimura Y, Zang L, Hirano M, Shimada Y, et al. (2010) Diet-induced obesity in zebrafish shares common pathophysiological pathways with mammalian obesity. BMC Physiol 10: 21.
17. Nakamura A, Unuyama T, Kato H, Nishino T, Oshita Y, et al. (2009) The first selective serotonin uptake inhibitor and an antidepressant drug: twenty years of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants. J Neurochem 21: 161–190.

Author Contributions

Conceived and designed the experiments: YS TT. Performed the experiments: YS MH. Analyzed the data: YS MH YN. Contributed reagents/materials/analysis tools: MH. Wrote the paper: YS YN TT.
58. Currie PJ, Braver M, Mirza A, Sricharoon K (2004) Sex differences in the reversal of fluoxetine-induced anorexia following raphe injections of 8-OH-DPAT. Psychopharmacology (Berl) 172: 359–364.

59. Myung CS, Kim BT, Choi SH, Song GY, Lee SY, et al. (2005) Role of neuropeptide Y and proopiomelanocortin in fluoxetine-induced anorexia. Arch Pharm Res 28: 716–721.

60. Lauzarica N, García-Garcia L, Fuentes JA, Delgado M (2012) Hypophagia and induction of serotonin transporter gene expression in raphe nuclei of male and female rats after short-term fluoxetine treatment. J Physiol Biochem 29: In press.

61. Shishkina GT, Kalinina TS, Dygalo NN (2012) Effects of swim stress and fluoxetine on 5-HT1A receptor gene expression and monoamine metabolism in the rat brain. Cell Mol Neurobiol 32: 787–794.

62. Heal DJ, Apley S, Prow MR, Jackson HC, Martin KF, et al. (1998) Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. International journal of obesity and related metabolic disorders. Int J Obes Relat Metab Disord 22 Suppl 1: S18–28; discussion S29.

63. Casado A, Rodriguez VM, Portillo MP, Macarulla MT, Aboxia LC, et al. (2003) Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins. Nutr Neurosci 6: 103–111.

64. Ampatzis K, Kentouri M, Dermon CR (2008) Neuronal and glial localization of alpha(2A)-adrenoceptors in the adult zebrafish (Danio rerio) brain. J Comp Neurol 508: 72–93.

65. Janhunen SK, van der Zwaal EM, la Fleur SE, Adan RA (2011) Inverse agonism at alpha2A adrenoceptors augments the hypophagic effect of sibutramine in rats. Obesity (Silver Spring) 19: 1979–1986.

66. Benkimoun P (2012) Appetite suppressant was probably responsible for 1300 deaths, study shows. BMJ 344: e996.

67. Gadde SM, Allison DB (2006) Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 114: 974–984.

68. Johansson K, Neovius K, DeSantis SM, Rossner S, Neovius M (2009) Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 10: 564–575.

69. Clements S, Schreck CB, Larsen DA, Dickhoff VW (2002) Central administration of corticotropin-releasing hormone stimulates locomotor activity in juvenile chinook salmon (Oncorhynchus tshawytscha). Gen Comp Endocrinol 127: 319–327.

70. van Rossum JM, Simons F (1969) Locomotor activity and anorexigenic action. Psychopharmacologia 14: 248–254.

71. Zambotti F, Carrafa MO, Barzaghi F, Vicentini L, Groppetti A, et al. (1976) Behavioural effects of a new non-phenylethylamine anorexigenic agent: mazindol. Eur J Pharmacol 36: 405–412.